Biote Corp. filings document the public-company disclosures of a Nasdaq-listed hormone optimization and healthy aging business. Recent Form 8-K reports furnish quarterly and annual operating results, including procedure revenue, dietary supplement revenue, margins, adjusted EBITDA measures and commercial-priorities commentary for the Biote-certified provider network.
The company’s SEC record also includes Regulation FD investor presentation filings, definitive proxy materials for annual meeting matters, and securities information for its Class A common stock. Other material-event filings address operational and financial effects of a voluntary recall involving specific hormone pellet lots shipped by Asteria Health, Biote’s wholly owned 503B manufacturer of compounded bioidentical hormones.
biote Corp. director Marc D. Beer received a grant of stock options covering 195,000 shares of Class A common stock. The options have an exercise price of $2.20 per share and were awarded at no cost to him.
All 195,000 option shares will vest on the earlier of May 12, 2027 or the day before biote Corp.’s 2027 annual meeting of stockholders, as long as he continues in service through that date. Following this grant, he holds 195,000 stock options directly.
biote Corp. director and ten percent owner Richard R. Barrera received a grant of stock options for 121,452 shares of Class A Common Stock at an exercise price of $2.20 per share. The options vest on the earlier of May 12, 2027 or the day before the 2027 Annual Meeting of Stockholders and expire on May 11, 2036.
biote Corp. files Amendment No. 3 to a Schedule 13G/A reporting beneficial ownership. The filing states that Bandera Partners LLC, and its Managing Members Gregory Bylinsky and Jefferson Gramm, report shared beneficial ownership of 2,065,482 shares of Class A common stock as of the close of business on March 31, 2026. The reported stake equals 6.4% of the class, calculated using 32,046,352 shares outstanding as of March 23, 2026 from the issuer's proxy statement. The statement clarifies that the shares are held by Bandera Master Fund L.P., that Bandera Partners is the fund's investment manager, and that the Reporting Persons disclaim beneficial ownership under certain rules.
biote Corp. reported weaker Q1 2026 results as a product recall and higher costs weighed on performance. Total revenue was $44.9 million, down from $49.0 million a year earlier, as pellet procedure revenue declined while dietary supplement sales grew.
Net income attributable to stockholders fell to $2.3 million from $13.7 million, or $0.06 diluted earnings per share versus $0.37. Management estimates the January 2026 voluntary recall of certain hormone pellets reduced pellet procedure revenue by about $1.7 million and added roughly $1.5 million of recall-related costs in the quarter.
Cash and cash equivalents dropped to $5.3 million from $24.1 million at year-end, largely reflecting an $18.5 million payment to settle share repurchase liabilities, $1.1 million of Class A share buybacks and term-loan repayments. Long-term debt includes a $101.6 million term loan and $5.0 million drawn on the revolving facility, and the company remains in a stockholders’ deficit position despite modest profit and $8.7 million of Adjusted EBITDA.
Biote Corp. reported first quarter 2026 revenue of $44.9 million, down 8.3% from $49.0 million, as procedure volumes were hurt by a voluntary recall of certain hormone pellet products. Gross margin slipped to 68.9% from 74.3%, and operating income fell to $3.2 million from $9.7 million.
Net income declined to $2.7 million (diluted EPS $0.06) from $15.8 million ($0.37), largely because the gain from changes in earnout liabilities dropped to $2.1 million from $10.7 million. Adjusted EBITDA was $8.7 million, a 36.6% decrease, with margin down to 19.4% from 28.1%.
Dietary supplements revenue grew 19.1% to $11.0 million, partly offsetting a 13.2% decline in procedure revenue to $31.3 million. Management reaffirmed 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million, and continues to expect procedure revenue to return to growth in the second half of 2026.
biote Corp. reported that General Counsel Daniel Michael Monico received a grant of 88,800 employee stock options for Class A common stock at an exercise price of $2.19 per share. Following the grant, he holds 88,800 options directly.
One-half of the options vest on April 27, 2028, with the remaining half vesting in 24 equal monthly installments after that date, contingent on his continued service. The options expire on April 30, 2036. This is a compensation-related award, not an open‑market purchase or sale.
biote Corp. filed an initial Form 3 showing that General Counsel Daniel Michael Monico beneficially owns 1 share of Class A Common Stock. The filing reports this direct holding as of April 27, 2026 and does not reflect any buy or sell transaction.
biote Corp. filed a report to share an updated investor presentation that outlines its 2025 performance and 2026 outlook. For 2025, the company reports revenue of $192.2 million and Adjusted EBITDA of $53.5 million, reflecting a 27.8% Adjusted EBITDA margin. The presentation also provides 2026 guidance, targeting revenue above $190 million and Adjusted EBITDA above $38 million, and describes Biote’s strategy to expand its hormone optimization and broader therapeutic wellness offerings through a scalable practitioner network and proprietary technology platform.
biote Corp. reported that Chief Executive Officer Bret Christensen received a grant of employee stock options. The award covers 441,653 options to buy Class A Common Stock at an exercise price of $1.43 per share, all held as direct ownership.
According to the vesting terms, 25% of the options will vest on April 1, 2027. The remaining options will then vest in 36 substantially equal monthly installments, contingent on Christensen’s continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.
biote Corp. Chief Financial Officer Robert Charles Peterson received a grant of 107,169 employee stock options for Class A Common Stock. The options have an exercise price of $1.43 per share and expire on March 31, 2036.
After this award, Peterson holds 107,169 derivative securities. According to the vesting schedule, 25% of the options vest on April 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, contingent on his continued service.